


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

LAPSE OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

Placing Agent



References are made to the announcements of Innovative Pharmaceutical Biotech Limited (the “**Company**”) dated 21 August 2025 and 29 August 2025 in relation to, among other things, the placing agreement entered into by the Company with CNI Securities Group Limited as the placing agent dated 21 August 2025 for up to 145,000,000 placing shares of the Company at the placing price of HK\$0.415 per placing share (the “**Announcements**”). Unless otherwise specified, the terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Board announces that as the conditions precedent as set out in the Placing Agreement were not fulfilled on or before 11 September 2025, the Placing Agreement has lapsed and the Placing will not proceed. All obligations of the Placing Agent and of the Company hereunder shall cease and determine and none of the parties shall have any claim against the other in relation to the Placing Agreement.

The Board is of the view that the lapse of the Placing Agreement will not cause any material adverse impact on the current operation and financial position of the Company.

By order of the Board
Innovative Pharmaceutical Biotech Limited
Yeung Yung
Chairman

Hong Kong, 11 September 2025

As at the date of this announcement, the Board comprises, Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director) Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkan, Tim (independent non-executive Director) and Ms. Sun Sizheng (independent non-executive Director).

Please also refer to the published version of this announcement on the Company's website: www.ipb.asia and www.irasia.com/listco/hk/ipb.